Form 4: Fulgent Genetics COO Sells Shares for Tax Obligations

Fulgent Genetics President and COO, Jian Xie, sold 681 shares of common stock to cover tax withholding obligations related to vested restricted stock units.

Summary

• Jian Xie, President and COO of Fulgent Genetics, Inc. (FLGT), reported the sale of 681 shares of common stock.
• The transaction occurred on November 24, 2025.
• The shares were sold at a weighted-average price of $30.473 per share, with individual sales ranging from $30.33 to $30.62.
• The purpose of the sale was to satisfy tax withholding obligations arising from the vesting of restricted stock units granted on February 23, 2023.
• Following the transaction, Mr. Xie directly beneficially owns 339,087 shares of common stock.
• Additionally, 220,816 shares are indirectly beneficially owned through The Hsieh Family Dynasty Trust, for which Mr. Xie serves on the investment committee.

Sentiment

Score: 6

Explanation: The transaction is a non-discretionary sale of a relatively small number of shares to cover tax obligations upon RSU vesting, which is a common and expected event for executives. It does not indicate a lack of confidence in the company's future.

Negatives

• An insider sale, even for tax purposes, reduces the executive's direct equity stake in the company.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 23, 2023.
• The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

Industry Context

This transaction is a routine insider filing common across all industries for executives receiving equity compensation. It reflects standard practice for managing tax liabilities associated with vested restricted stock units, rather than a specific industry trend or competitive action.

Related Party Transactions

• The Hsieh Family Dynasty Trust, dated January 27, 2010, holds 220,816 shares indirectly beneficially owned by Mr. Xie, who serves on its investment committee. This represents an ongoing related party holding, though no transaction by the trust is reported here.

Stakeholder Impact

• Minimal impact on shareholders as the sale is small and for tax purposes, not a discretionary divestment. Employees and customers are not directly impacted by this specific filing.

Next Steps

• The reporting person undertakes to provide full information regarding the number of shares and prices upon request to the SEC staff, the Issuer, or a security holder.

Key Dates

Recommendation

This Form 4 reports a routine, non-discretionary sale of a small number of shares by an executive to cover tax obligations upon the vesting of restricted stock units. Such transactions are common and do not typically signal a change in the company's fundamental outlook or the executive's confidence. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

Fulgent Genetics, FLGT, insider trading, Form 4, stock sale, executive compensation, restricted stock units, tax withholding, Jian Xie, President, COO